Analyst Ryan Langston of TD Cowen maintained a Hold rating on Amedisys (AMED – Research Report), retaining the price target of $101.00.
Ryan Langston’s rating is based on a combination of factors that reflect Amedisys’s recent financial performance and market conditions. The company reported an adjusted EBITDA that exceeded expectations, driven by lower general and administrative expenses. However, the adjusted net service revenue fell slightly short of consensus estimates, indicating mixed results in financial metrics.
Despite the positive EBITDA margin improvements, the lack of formal guidance from Amedisys following its merger announcement adds uncertainty to future performance projections. Additionally, while certain segments like Hospice showed revenue growth, other areas such as same-store volumes and cost per visit presented challenges. These mixed signals, along with the unchanged price target reflecting the acquisition offer, contribute to the Hold rating, suggesting a cautious approach while awaiting more clarity on future operations.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMED in relation to earlier this year.